Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Skin and Connective Tissue Diseases

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Small Cell Lung Carcinoma

Melanoma

Carcinoma, Transitional Cell

Stomach Neoplasms

Carcinoma, Renal Cell

Lung Neoplasms

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Small Cell Lung Cancer

Transitional Cell Carcinoma

Renal Cell Carcinoma

Stomach Cancer

Clear Cell Renal Cell Carcinoma

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Pembrolizumab

Antibodies

Immunoglobulins

Immunoglobulin G

Immunoglobulins, Intravenous

Antibodies, Blocking

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Conditionally active biologic (CAB) antibody that binds to CTLA-4

Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor

BA3071

Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1

Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor

BioAtla Medical Affairs

Misty Guillen

Roland Menendez

Inderjit Mehmi, MD

Diane Chun

Jacob Thomas, MD

Dionne Jean

Sharon Joseph

Eyal Meiri, MD

Lynley Bell

Costantine Albany, MD

Kimberly Thomas

Jennifer Selfridge, MD

Annie Stadum

Kim Sutcliffe

Matthew Taylor, MD

Susan Sharry

Siwen Hu-Lieskovan, MD, PhD

Amy Erskine

Paul DeSousa, MD

Daniel Clark

Vineet Kwatra, MD

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3071 in combination with a PD-1 blocking antibody, nivolumab, in patients with advanced solid tumors.

A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

BioAtla, Inc.

Antibodies, Monoclonal

Ipilimumab

BMS-986207

Bristol-Myers Squibb

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Ono Pharmaceutical Co. Ltd

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors	NCT05180799	Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma	BA3071 Nivolumab Pembrolizumab	18 Years -	BioAtla, Inc.
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors	NCT02913313	Broad Solid Tum...	BMS-986207 Nivolumab Ipilimumab	18 Years -	Bristol-Myers Squibb

Spots Global Cancer Trial Database for first line nsclc